News

For more information please contact us at the following email address: contact@ablsa.com

LNS ET ABL DÉVELOPPENT UNE SOLUTION DE DIAGNOSTIC COMMUNE DANS LA LUTTE CONTRE LA COVID-19

Le Laboratoire national de santé (LNS) et Advanced Biological Laboratories (ABL) s’associent dans la lutte contre la COVID-19. A cette fin, les deux laboratoires ont signé un accord qui prévoit le développement d’une solution de diagnostic intégrée. Le projet, appelé INNOV-COV-ID, est cofinancé par…

Advanced Biological Laboratories (ABL) S.A. and An Binh Medical are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Vietnam. See current channel partners.

Première région touchée par la pandémie, le Grand Est est également la première région qui a mobilisé avec succès, depuis le début de la crise sanitaire, l’intégralité de son écosystème santé avec le soutien du pôle de compétitivité BioValley France. La COVID-19 nous prouve aujourd’hui que le dévelo…

You are a new Client ? This offer is made for you !! Get your free sample kit among all our microbiology genotyping assays  (SANGER or Next Generation Sequencing)                                   Offer Available Un…

Advanced Biological Laboratories (ABL) S.A. and Roche Diagnostics are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Portugal. See current channel partners.

For more information please contact us at the following email address: contact@ablsa.com  

We are pleased to announce the availability of the DeepChek® Assay Whole Genome SARS-CoV-2 Genotyping  and the DeepChek® CoV2 Software. Both combined, it offers an innovative end-to-end solution (for Research Use Only (RUO)) for SARS-CoV-2 whole genome sequencing and analysis: from SARS-CoV-2 whole-…

We are pleased to announce the immediate availability of the DeepChek®-HIV Solution combining CE-IVD target-specific amplification assays with data interpretation software both compatible with SANGER and Next Generation Sequencing (NGS) platforms. For more informations or to build a project for your…

We are pleased to announce the immediate availability of robust, cost-effective  & open instruments for SARS-CoV-2 detection and other applications.   CleanPrepX : a magnetic bead-based automated extractor for all your samples Manual or automated workflow Template compatibility : Serum, pla…

Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols Caputo et al. Virology Journal (2020) 17:103 https://doi.org/10.1186/s12985-020-01381-3 Abstract Background: Notwithstanding the efforts of direct-acting antivirals (DAAs) for…

We are pleased to announce that Nimagen appointed ABL as its exclusive distribution partner for Sequencing Products in France, Belgium and Luxembourg. The partnership was formalized on March 17th 2020 and will help all labs involved in sequencing to get access to robust and cost-effective solutions…

A unique and flexible solution adapted to all virology and microbiology laboratories   LUXEMBOURG CITY (Luxembourg), METZ (France) — May 18th, 2020 — Advanced Biological Laboratories (ABL) announced today the CE-IVD marking of its DeepChek®-HIV assays, now available for in-vitro diagnostics.  Intend…

ABL is pleased to announce two major updates on its HIV Genotyping Software applications : the full integration of the ViroScore® and DeepChek® software applications with Nadis the availability of a new web-based and disease-specific chromatogram editor

Meet us at MEDICA 2019 for Leveraging your Infectious Diseases Genotyping Capacities   Good morning, ABL will be attending the next MEDICA forum in Düsseldorf from 18 – 21 November 2019 (Hall 3 / A74).  We will be pleased to have a chance to meet you there and explain you in detail the SA…